title: Development of Small-Molecule Antivirals for Ebola.
abstract: Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti-Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small-molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T-705).
authors.affiliation: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i. Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Janeba
mesh_terms: D000354:Africa, Western / Q000453:epidemiology; D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000627:therapeutic use*; D004196:Disease Outbreaks; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000453:epidemiology; D057166:High-Throughput Screening Assays; D006801:Humans
chemical_list: D000998:Antiviral Agents
keywords: Ebola virus; Marburg virus; antiviral; filovirus; hemorrhagic fever